Eric brings approximately 20 years of experience in the healthcare industry focusing on value demonstration, product commercialization, and market access/reimbursement. At Evidera, he focuses on health technologies with significant disruptive potential which have complex access issues or requirements such as personalized medicine, diagnostics, orphan drugs, combination products, cell therapy and regenerative medicine, immuno-oncology and vaccines, and e-connectivity technologies.
Prior to joining Evidera, Eric held several senior level positions at Quintiles, including Practice Leader, Emerging Technology Value Demonstration, Access and Commercialization and Principal, Global Market Access and Commercialization, where he developed and led a cross-functional practice including clinical, late-phase, and commercial business units focused on emerging technology product support. He has also held roles at RTI Health Solutions, Littell Group, Inc., and The Lewin Group where he was responsible for evidence-generation solutions to support the approval and market access of pharmaceutical and medical device products.
Eric’s prior project work has included global market access and commercial strategy analysis, qualitative and quantitative research, evidence-based practice and policy, design of clinical trials to meet third-party decision requirements, real-world evidence strategy and implementation, life sciences portfolio due diligence, and modeling/decision support. Eric has also led health policy assessments, including CMS’s Coverage with Evidence Development (CED) and Clinical Trial Policy, value-based purchasing, competitive bidding, cost-effectiveness, comparative effectiveness, and pharmacogenomics for life sciences manufacturers, industry and medical professional associations, and government agencies, including HHS, NIH, FDA, CDC, and ASPE. He has also served as a global payer expert for emerging technologies for various global industry and EU government groups.
Eric is a recognized global thought leader in personalized medicine, regenerative medicine, biopharmaceutical, medical and emerging technology market access, with extensive publication and over 70 global panel sessions on these topics. He has recently served as an expert advisor to the Personalized Medicine Subcommittee of the President’s Council of Advisors on Science and Technology, advised the Austrian government on personalized medicine policy for oncology, and served on the Leadership Committee for the Business Models and Reimbursement Working Group of the International Society for Cellular Therapy. He serves on the Leadership Committees of the HTA and the Medical Devices Special Interest Groups, as Co-Chair of the Diagnostics Special Interest Group, and formerly as the Chair of ISPOR’s Personalized Medicine Special Interest Group (now a Leadership Committee member).
Eric also serves as an adjunct Assistant Professor for the Institute for Pharmacogenomics and Individualized Therapy at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill and as the Executive Director of the Genomics Biotech and Emerging Medical Technology Institute of the National Association of Managed Care Physicians, one of the largest US payer leadership bodies which includes a 90 commercial payer Executive Leadership Council and approximately 25 manufacturer members from all health technology sectors.